EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Femasys Inc (FEMY) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Femasys Inc $0.45, price $2.48, upside -81.8%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US31447E1055

FI Femasys Inc logo Thin data Sep 27, 2026

Femasys Inc

FEMY · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.4505 · Strongly overvalued (−81.8%)
!Quality 23/100
!Expensive Growth (revenue 5y +17.2 %/yr)
!Moderate debt · negative free cash flow
!Trails peers (1/8)
!Narrow moat 9/100
!Insider activity 30/100
!Evidence only low, so the estimate is less certain
Watch Femasys Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$197.80 $2.16 Fair Value $0.4505 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $2.16 – $197.80 · fair‑value band $0.2975 – $0.5610 · the $2.48 price screens above the $0.4505 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Femasys in your weekly email

Every Wednesday you see whether Femasys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally.

Show more

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Stock analysis

Femasys Inc (FEMY) currently trades at $2.48, while our model-based Fair Value estimate is $0.4505, implying the stock looks roughly 450.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.2975 (bear) to $0.5610 (bull), the price of $2.48 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Femasys Inc reported revenue of $2.3M in FY2025 versus $1.2M in FY2021, a compound +18.1%/yr. Reported net income was −$18.6M in FY2025.

Key figures

Market cap $12.2M · P/S ratio 5.13 · EPS (TTM) $−4.80 · Return on equity −256% · Return on assets (EBIT) −75.6% · Operating margin −994% · Revenue (TTM) $2.4M · Revenue growth (YoY) +24.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 88% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at −82%, FEMY screens richer than that median.

Fair Value models

Bear $0.2975 Fair Value $0.4505 Bull $0.5610
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.9700 $1.30 $1.94 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.9700 $1.30 $1.94 54

Open the full fair value analysis →

Notify me when FEMY reaches fair value

Put FEMY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 26 · Market factors (momentum, volatility) 16

Profitability 3
Margins and returns on capital today
Quality Growth 69
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 40
Balance sheet, leverage, solvency risk
Investment 55
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+40.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−668.0% (2020) → −767.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

FEMY screens 450% overvalued. Compare with Intuitive Surgical, Inc →

Compare Femasys Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −81.8% · Bottom 25%
Profitability
Return on assets −68.7% · Bottom 25%
Growth and dividend
Revenue growth 24.5% · Top 25%
Balance sheet
Debt / equity 0.54× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.08× · Pricier than median
P/S (TTM) 5.13× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)73 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $405.18 $348.72 −14%
EssilorLuxottica Société anonyme EL €143.90 €158.29 +10%
Becton, Dickinson and Company BDX $183.82 $104.73 −43%
Medline Inc MDLN $34.70 $29.06 −16%
ResMed Inc RMD A$31.58 A$34.74 +10%
Alcon Inc ALC $64.47 $40.13 −38%
West Pharmaceutical Services, Inc WST $370.44 $137.81 −63%
Sartorius Stedim Biotech S.A DIM €212.40 €54.82 −74%
Straumann Holding STMN CHF 97.48 CHF 45.50 −53%
Sartorius Aktiengesellschaft SRT €206.50 €42.05 −80%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Femasys Inc · Fair Value
$0.4505 −450%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Femasys Inc Fair Value". https://www.fairvalue-calculator.com/stock/FEMY

Frequently asked questions

Is Femasys Inc (FEMY) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.4505 versus a price of $2.48, about −82% upside (overvalued).
What is the fair value of FEMY?
Our model-based fair value for Femasys Inc is $0.4505 (as of Sep 27, 2026), built from audited fundamentals. The current price: $2.48.
What is the quality score of FEMY?
Femasys Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Femasys Inc (FEMY)?
Our model-based price target is the fair value of $0.4505 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.2975, optimistic scenario $0.5610. It is a calculation from audited fundamentals, not an analyst target.
What is the Femasys Inc stock forecast for 2026?
Our models put fair value at $0.4505, about −82% upside versus a price of $2.48 (overvalued). Cautious scenario $0.2975, optimistic scenario $0.5610. The calculation is refreshed regularly with new filings.
What is the revenue of Femasys Inc (FEMY)?
Femasys Inc reported trailing-twelve-month revenue of about $2.4M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Femasys Inc (FEMY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Femasys Inc it is $0.4505 per share (as of Sep 27, 2026), against a price of $2.48. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Femasys Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, FEMY trades above its calculated fair value: price $2.48, fair value $0.4505, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FEMY?
No. The price is what the market pays today ($2.48); the fair value is what the company's own numbers justify ($0.4505). For Femasys Inc the two are $2.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Femasys Inc worth?
The market values Femasys Inc at about $12.2M (market capitalisation, as of Sep 27, 2026). Per share that is $2.48; our models calculate a fair value of $0.4505 per share.
What do the bullish and bearish scenarios say about FEMY?
Our models span a range for Femasys Inc: cautious scenario $0.2975, base $0.4505, optimistic $0.5610 per share (as of Sep 27, 2026, price $2.48). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Femasys Inc (FEMY)?
Balance-sheet figures for Femasys Inc (as of Sep 27, 2026): return on equity −256.0%, debt of 0.54 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is FEMY from its 52-week high?
Femasys Inc trades at $2.48, about 88% below its 52-week high of $20.80 and 15% above the low of $2.16 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4505 is for.
Which stocks are comparable to Femasys Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Femasys Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $2.48, calculated fair value $0.4505 (−82%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FEMY calculated?
We run Femasys Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4505, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Femasys Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Femasys Inc (FEMY)?
The closing price on Sep 25, 2026 was $2.48. Our model-based fair value is $0.4505, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Femasys Inc right now?
The price sits above even our optimistic bull case ($0.5610). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2975 to $0.5610) leaves room in how you read the outcome.

Key figures of Femasys Inc

How large is the market capitalisation of Femasys Inc (FEMY)?
The market capitalisation of Femasys Inc is $12.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Femasys Inc (FEMY)?
The price-to-sales ratio of Femasys Inc is 5.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Femasys Inc (FEMY)?
Earnings per share at Femasys Inc are $−4.80. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Femasys Inc (FEMY)?
The return on equity (ROE) of Femasys Inc is −256% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Femasys Inc (FEMY)?
On an EBIT basis the return on assets of Femasys Inc is −75.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Femasys Inc (FEMY)?
The operating margin of Femasys Inc is −994% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Femasys Inc (FEMY)?
Revenue at Femasys Inc is growing +24.5% versus a year earlier (3y avg +23.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Femasys Inc (FEMY) generate?
The free cash flow of Femasys Inc is −$19.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Femasys Inc (FEMY) hold?
Femasys Inc holds more cash than debt, $4.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Femasys Inc in the live analysis

One click puts Femasys Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.